iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Author:

Hallek Michael12,Cheson Bruce D.3,Catovsky Daniel4,Caligaris-Cappio Federico5,Dighiero Guillermo6,Döhner Hartmut7,Hillmen Peter8,Keating Michael9,Montserrat Emili10,Chiorazzi Nicholas11,Stilgenbauer Stephan7,Rai Kanti R.11,Byrd John C.12,Eichhorst Barbara1,O’Brien Susan13,Robak Tadeusz14,Seymour John F.15,Kipps Thomas J.16

Affiliation:

1. Klinik I für Innere Medizin, Universität zu Köln, Cologne, Germany;

2. Center of Excellence for Cellular Stress Responses in Aging-Associated Diseases, Köln, Germany;

3. Lombardi Cancer Center, Georgetown University Hospital, Washington, DC;

4. Institute of Cancer Research, London, United Kingdom;

5. Department of Oncohematology, Universita Vita-Salute San Raffaele, Milan, Italy;

6. Institut Pasteur, Montevideo, Uruguay;

7. Department III of Internal Medicine, University of Ulm, Ulm, Germany;

8. St James’s Institute of Oncology, Leeds, United Kingdom;

9. Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX;

10. Hospital Clinic, University of Barcelona, Barcelona, Spain;

11. Feinstein Institute for Medical Research, Manhasset, NY;

12. Division of Hematology, The Ohio State University, Columbus, OH;

13. Division of Hematology/Oncology, School of Medicine, University of California, Irvine, CA;

14. Department of Hematology, Medical University of Lodz, Lodz, Poland;

15. Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia; and

16. Rebecca and John Moores Cancer Center, University of California, San Diego, La Jolla, CA

Abstract

Abstract The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with prognostic relevance, and the detection of minimal residual disease (MRD), coupled with the increased availability of novel targeted agents with impressive efficacy, prompted an international panel to provide updated evidence- and expert opinion–based recommendations. These recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 1030 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3